Genetic testing for breast cancer predisposition.
The recent identification of the BRCA1 and BRCA2 genes has improved our understanding of the association between breast and ovarian cancers in certain families. Carriers of predisposing germline mutations must decide on different options for management, including close follow-up or prophylactic surgery. Further studies are needed to elucidate the optimal management of these patients and to identify the factors that modify their risk for developing breast cancer. Finally, we must work to prevent any form of discrimination against those who, following genetic testing, are found to be at increased risk for breast cancer.
Gauthier-Villars
M
M
Service de Génétique Oncologique, Institut Curie, Paris, France. dominique.lyonnet@curie.net
Gad
S
S
Caux
V
V
Pagès
S
S
Blandy
C
C
Stoppa-Lyonnet
D
D
D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1 / Q000235:genetics; D005817:Genetic Counseling; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D018095:Germ-Line Mutation / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics; D011287:Prejudice; D011379:Prognosis; D012307:Risk Factors; D014157:Transcription Factors / Q000235:genetics
D024682:BRCA2 Protein; D005819:Genetic Markers; D009363:Neoplasm Proteins; D014157:Transcription Factors